Author

A. Upton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 1

Frequent Co-Authors

E. Nuermberger· 4 shared N. Fotouhi· 4 shared P. J. Converse· 4 shared K. Mdluli· 3 shared R. Tasneen· 2 shared S.-Y. Li· 2 shared B. Urones· 1 shared D. Barros-Aguirre· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

E. Nuermberger

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

S.-Y. Li, P. J. Converse, F. Betoudji, J. Lee, K. Mdluli, A. Upton, N. Fotouhi, E. Nuermberger

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

bioRxiv · Jan 10, 2023 · PreprintMicrobiology

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

E. Nuermberger, M. S. Martinez, O. Sanz, B. Urones, J. Esquivias, H. Soni, R. Tasneen, S. Tyagi, S.-Y. Li, P. J. Converse, H. I. Boshoff, G. T. Robertson, G. Besra, K. A. Abrahams, A. Upton, , E. N. Jimenez

Antimicrobial Agents and Chemotherapy · Jun 21, 2022Peer-reviewedPharmacology & Toxicology

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

R. Tasneen, D. S. Mortensen, P. J. Converse, M. E. Urbanowski, A. Upton, N. Fotouhi, E. Nuermberger, N. Hawryluk

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

bioRxiv · Feb 10, 2021Pathology

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

J. Xu, P. J. Converse, A. Upton, K. Mdluli, N. Fotouhi, E. Nuermberger

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

bioRxiv · Nov 17, 2020Microbiology